RxDoctor Payments Data

Brittany Carnahan

Nurse Practitioner · Helena, MTNPI 1841801370

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 171 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AstraZeneca at 26.9% of the total. 2025 is the largest year on record at $932, 4.7 times the $197 reported in 2021. Among nurse practitioner clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,034in general payments, 2019–2025

Across 171 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$815
  • AbbVie$458
  • Novo Nordisk$409
  • Lilly USA, LLC$337
  • Pfizer$130
  • Astellas Pharma US Inc$125
  • plus $760 from 14 others

What the payments were for

  • Food & beverage$3,034100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,034 in reported general payments places this provider in the 95th percentile of 357 nurse practitioner providers in Montana.

See all nurse practitioner providers in Montana

Medicare billing

Part B allowed, 2024
$62,900
Medicare patients
200
Services billed
1,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$44,041
MounjaroTirzepatide41$43,199
JardianceEmpagliflozin59$18,914
OzempicSemaglutide14$14,856
EliquisApixaban15$14,095
FarxigaDapagliflozin Propanediol52$7,727
Levothyroxine Sodium199$1,738
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen78$1,707
Potassium Chloride134$1,436
Albuterol Sulfate HfaAlbuterol Sulfate40$1,256
Enalapril Maleate59$1,136
Simvastatin134$1,018
SynthroidLevothyroxine Sodium11$908
Estradiol31$818
Omeprazole76$667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$118$44,04143 claims
Lilly USA, LLCMounjaro$337$43,19941 claims
Novo NordiskOzempic$409$14,85614 claims
PfizerEliquis$130$14,09515 claims
AstraZenecaFarxiga$815$7,72752 claims
AbbVieSynthroid$458$90811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 357 nurse practitioner providers in Montana.

Other nurse practitioner in Helena

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →